BioTuesdays

Category - Feature

Feature

Stereotaxis sees Japanese reimbursement by year end

After receiving regulatory clearance in Japan of its Niobe Remote Magnetic Navigation system for cardiac ablations last March, Stereotaxis (NASDAQ:STXS) now expects to achieve reimbursement approval by the end of the...

September 3, 2013
Feature

In conversation with Rudy Mazzocchi

As president and CEO of closely-held ELENZA, Rudy Mazzocchi knows a thing or two about taking startups across the finish line. Among other things, he was the founder of eV3, which is now part of Covidien, and co-founder...

August 27, 2013
Feature

Galectin targets silent epidemic in liver fibrosis

Fatty liver disease, or the accumulation of fat in liver cells, is a “silent epidemic,” says Dr. Peter Traber, president, CEO and chief medical officer of Galectin Therapeutics (NASDAQ:GALT). In an interview with...

August 20, 2013
Feature

RedHill readying Phase 3 trials in Crohn’s

With a PDUFA target date of Feb. 3, 2014 for its migraine drug, RHB-103, and NDA filing planned for the first quarter of 2014 for the anti-emetic drug, RHB-102, RedHill Biopharma (NASDAQ,:RDHL; TASE:RDHL) is now...

August 13, 2013
Feature

Elite eyes home run in abuse-resistant technology

After reinventing itself in 2011, Elite Pharmaceuticals (OTCBB:ELTP) has bounced back with a line of generic drugs and is banking on the development of abuse-resistant opioids and once-daily opioid products to fuel its...

August 6, 2013
Feature

In conversation with Todd Wyche

As CEO and a co-founder of Brinson Patrick Securities, Todd Wyche has championed the use and growth of at-the-market offerings (ATMs) for the past 17 years for REITs, energy companies and most recently, biotech and life...

July 2, 2013
Feature

Avivagen shifts to commercial mindset from R&D

Cameron Groome, who moved into the executive suite at Avivagen (TSX-V:VIV) in March, has transformed the focus of the animal wellness company to a business and product development engine and away from an earlier...

June 18, 2013
Feature

Oramed readies oral insulin study in U.S.

Oramed Pharmaceuticals (NASDAQ:ORMP) is awaiting a decision from the FDA, possibly later this week, to conduct a sub-study of the safety of its oral insulin candidate, ORMD-0801, before proceeding to a large, multi...

May 7, 2013